Human–SCID mouse chimeric models for the evaluation of anti-cancer therapies

This publication has 50 references indexed in Scilit:

• Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using125I-labeled anti-endoglin monoclonal antibodies
  International Journal of Cancer, 1999
• THE SCID MOUSE REACTION TO HUMAN PERIPHERAL BLOOD MONONUCLEAR LEUKOCYTE ENGRAFTMENT
  Transplantation, 1995
• Survival of human prostate carcinoma, benign hyperplastic prostate tissues, and IL‐2‐activated lymphocytes in SCID mice
  The Prostate, 1995
• Inhibition of Human Colon Cancer Growth by Antibody-Directed Human LAK Cells in SCID Mice
  Science, 1993
• Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation.
  The Journal of Experimental Medicine, 1992
• Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: Growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells
  Cancer Immunology, Immunotherapy, 1992
• Human‐mouse lymphoid chimeras: host‐vs.‐graft and graft‐vs.‐host reactions
  European Journal of Immunology, 1992
• Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood.
  The Journal of Experimental Medicine, 1992
• The scid mutation in mice causes a general defect in DNA repair
  Nature, 1990
• Establishment of a Human Cutaneous T-Cell Lymphoma in C.B-17 SCID Mice
  Journal of Investigative Dermatology, 1990